Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

10x Genomics (TXG) Revenue (2018 - 2026)

10x Genomics' Revenue history spans 8 years, with the latest figure at $166.0 million for Q4 2025.

  • On a quarterly basis, Revenue rose 0.61% to $166.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $642.8 million, a 5.25% increase, with the full-year FY2025 number at $642.8 million, up 5.25% from a year prior.
  • Revenue hit $166.0 million in Q4 2025 for 10x Genomics, up from $149.0 million in the prior quarter.
  • Over the last five years, Revenue for TXG hit a ceiling of $184.0 million in Q4 2023 and a floor of $105.8 million in Q1 2021.
  • Historically, Revenue has averaged $144.0 million across 5 years, with a median of $147.9 million in 2023.
  • Biggest five-year swings in Revenue: surged 170.0% in 2021 and later dropped 10.3% in 2024.
  • Tracing TXG's Revenue over 5 years: stood at $143.5 million in 2021, then increased by 8.85% to $156.2 million in 2022, then grew by 17.76% to $184.0 million in 2023, then dropped by 10.3% to $165.0 million in 2024, then rose by 0.61% to $166.0 million in 2025.
  • Business Quant data shows Revenue for TXG at $166.0 million in Q4 2025, $149.0 million in Q3 2025, and $172.9 million in Q2 2025.